Subscribe
canbedone
canbedone / shutterstock.com
9 July 2020John Stone

Trade secrets: an alternative for life sciences IP?

Over the past decade, three high-profile US Supreme Court decisions—known by their shorthand names as Alice, Mayo, and Myriad—have generated significant uncertainty over what is and isn’t patentable.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Former Genentech employee cuts plea deal with FBI in trade secrets case
16 January 2020   A former Genentech employee has pleaded guilty to a reduced charge after offering "superseding information" to the FBI as part of an ongoing trade secrets investigation.
Big Pharma
Allergan says rivals using trade secrets disclosed by USITC order
13 August 2019   Allergan has filed a motion asking for its “trade secrets” to be removed from evidence in a dispute over its wrinkle treatment, Botox.
Americas
Children’s hospital researcher admits selling trade secrets to China
3 August 2020   A former researcher at the research institute of the Nationwide Children’s Hospital in Ohio has pleaded guilty to conspiring to steal scientific trade secrets to sell in China.


Editor's picks

Americas
Comparing life sciences IP in Brazil and the US
28 November 2024

Editor's picks

Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024

More on this story

Big Pharma
Former Genentech employee cuts plea deal with FBI in trade secrets case
16 January 2020   A former Genentech employee has pleaded guilty to a reduced charge after offering "superseding information" to the FBI as part of an ongoing trade secrets investigation.
Big Pharma
Allergan says rivals using trade secrets disclosed by USITC order
13 August 2019   Allergan has filed a motion asking for its “trade secrets” to be removed from evidence in a dispute over its wrinkle treatment, Botox.
Americas
Children’s hospital researcher admits selling trade secrets to China
3 August 2020   A former researcher at the research institute of the Nationwide Children’s Hospital in Ohio has pleaded guilty to conspiring to steal scientific trade secrets to sell in China.

More on this story

Big Pharma
Former Genentech employee cuts plea deal with FBI in trade secrets case
16 January 2020   A former Genentech employee has pleaded guilty to a reduced charge after offering "superseding information" to the FBI as part of an ongoing trade secrets investigation.
Big Pharma
Allergan says rivals using trade secrets disclosed by USITC order
13 August 2019   Allergan has filed a motion asking for its “trade secrets” to be removed from evidence in a dispute over its wrinkle treatment, Botox.
Americas
Children’s hospital researcher admits selling trade secrets to China
3 August 2020   A former researcher at the research institute of the Nationwide Children’s Hospital in Ohio has pleaded guilty to conspiring to steal scientific trade secrets to sell in China.

More features

Comparing life sciences IP in Brazil and the US
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
China’s new policies on foreign investment in healthcare and biotech
Startup CFO’s betrayal is a lesson in preparing for the worst
10x Genomics counsel: ‘Winning cases is a top priority’
HR, lobbying and business strategy…all in a day’s work for today’s counsel
LSPN Fall: Why Big Pharma is facing 'a balancing act'
How post-filing data rescued Novo Nordisk’s Ozempic patent in China